A Study of JNJ-55308942 in the Treatment of Bipolar Depression

Completed · Phase 2 · Has a placebo group

Conditions studied: Bipolar Disorder

In brief

The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.

Key facts

Study ID
NCT05328297
Run by
Janssen Pharmaceutica N.V., Belgium
People needed
116
Starts
2022-06-03
Expected to finish
2024-05-17
Last updated by the study team
2025-07-11

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.